Company intelligence / Profile preview

NYQMC

Nassau, The Bahamas

Ownership: Private
Development stage: Other

Overview

Nymox’s lead candidate, Fexapotide Triflutate (FT), has completed Phase 3 clinical trials in over 1,700 patients across more than 70 U.S. centers for benign prostatic hyperplasia. The company plans to file for regulatory approval in major markets including the U.S. and Europe. FT has also shown long-term benefits in a Phase 2 trial for early-stage prostate cancer with significant delay of disease progression compared to controls. The company also markets diagnostic tests NicAlert® and TobacAlert®.

Therapeutic areas: Men's HealthPulmonologyOncologyNeurology
Modalities: Small molecule (Fexapotide Triflutate)Diagnostic test
Industry: Biotech

Beyond the preview

Go deeper on NYQMC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NYQMC.

Explore the full profile